NCT03013218

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Completed Phase 1 Last updated 1 August 2025

What this trial tests

Phase 1 trial testing Evorpacept (ALX148) in Metastatic Cancer in 174 participants. Completed in 8 July 2025.

Timeline

3 February 2017

Primary endpoint
1 February 2022

8 July 2025

Quick facts

Lead sponsor	ALX Oncology Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	174
Start date	3 February 2017
Primary completion	1 February 2022
Estimated completion	8 July 2025
Sites	10 locations across United States, South Korea

Drugs / interventions tested

• Evorpacept (ALX148) — full drug profile →
• Pembrolizumab (pembrolizumab) — full drug profile →
• Trastuzumab (trastuzumab) — full drug profile →
• Rituximab — full drug profile →
• Ramucirumab + Paclitaxel
• 5-FU + Cisplatin

Conditions studied

• Metastatic Cancer — all drugs for Metastatic Cancer →
• Solid Tumor — all drugs for Solid Tumor →
• Advanced Cancer — all drugs for Advanced Cancer →
• NonHodgkin Lymphoma — all drugs for NonHodgkin Lymphoma →

Sponsor

ALX Oncology Inc. — full company profile →

Who can join

18 and older, any sex, with Metastatic Cancer or Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Macrophages as regulators of tumour immunity and immunotherapy.
   DeNardo DG, Ruffell B. · · 2019 · cited 1903× · PMID 30718830 · DOI 10.1038/s41577-019-0127-6
2. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
   Alsaab HO, Sau S, Alzhrani R, Tatiparti K, et al · · 2017 · cited 1206× · PMID 28878676 · DOI 10.3389/fphar.2017.00561
3. Phagocytosis checkpoints as new targets for cancer immunotherapy.
   Feng M, Jiang W, Kim BYS, Zhang CC, et al · · 2019 · cited 729× · PMID 31462760 · DOI 10.1038/s41568-019-0183-z
4. Progress in tumor-associated macrophage (TAM)-targeted therapeutics.
   Ngambenjawong C, Gustafson HH, Pun SH. · · 2017 · cited 659× · PMID 28449873 · DOI 10.1016/j.addr.2017.04.010
5. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance.
   Wang S, Wang J, Chen Z, Luo J, et al · · 2024 · cited 406× · PMID 38341519 · DOI 10.1038/s41698-024-00522-z
6. Next generation of immune checkpoint inhibitors and beyond.
   Marin-Acevedo JA, Kimbrough EO, Lou Y. · · 2021 · cited 401× · PMID 33741032 · DOI 10.1186/s13045-021-01056-8
7. Drugging the efferocytosis process: concepts and opportunities.
   Mehrotra P, Ravichandran KS. · · 2022 · cited 319× · PMID 35650427 · DOI 10.1038/s41573-022-00470-y
8. The Role of the Extracellular Matrix in Cancer Stemness.
   Nallanthighal S, Heiserman JP, Cheon DJ. · · 2019 · cited 262× · PMID 31334229 · DOI 10.3389/fcell.2019.00086